The company provides a High‑Definition PCR (HDPCR™) platform that delivers over four‑fold multiplexing of DNA and RNA biomarkers using standard PCR instruments, enabling comprehensive genomic profiling without dedicated hardware. Its cloud‑based analytics suite automates assay interpretation, quality control, and reporting in a HIPAA‑ and ISO‑compliant environment, offering a faster, lower‑cost alternative to NGS for oncology, MRD, and disease‑monitoring applications in clinical laboratories.
Funding
Funding not disclosed
Founders
Product
Problem
Clinical laboratories face constraints in delivering comprehensive genomic profiling because conventional digital PCR (dPCR) offers limited multiplexing, while next‑generation sequencing (NGS) incurs high per‑sample costs and long turnaround times. These limitations hinder timely biomarker detection for oncology, minimal residual disease (MRD), and other disease‑monitoring applications.
Solution
The company offers a High‑Definition PCR (HDPCR™) multiplexing platform that combines proprietary chemistry, reagent kits, and a cloud‑based software suite to enable instrument‑agnostic, high‑content assays. By delivering more than four‑fold multiplexing over standard dPCR, the platform can interrogate dozens of DNA and RNA variants in a single run, reducing hands‑on time and achieving sub‑24‑hour results. Automated data interpretation in the ChromaCode Cloud eliminates manual analysis, while secure, HIPAA‑ and ISO‑compliant data handling supports clinical deployment. The solution is positioned as a cost‑effective alternative to NGS for tumor profiling, MRD detection, and longitudinal disease monitoring, allowing labs to increase throughput and improve margins without additional hardware investment.
Target Audience
Primary customers are clinical and reference laboratories that perform molecular diagnostics for oncology, MRD, and disease‑monitoring, as well as pharmaceutical R&D teams developing customized genomic assays.
Features
- Proprietary HDPCR chemistry that enables >4× multiplexing compared with conventional dPCR, supporting simultaneous detection of multiple DNA and RNA biomarkers.
- Instrument‑agnostic workflow requiring only standard PCR equipment; no dedicated hardware installation needed.
- Cloud‑native analytics platform that performs automated assay interpretation, quality control, and report generation via a secure, HIPAA‑ and ISO‑13485‑compliant environment.
- Ready‑to‑use reagent kits for oncology panels, MRD assays, and disease‑monitoring panels, customizable for pharma and research applications.
- Turnaround time under 24 hours with minimal manual steps, facilitating rapid clinical decision‑making.
- Scalable throughput that lowers cost‑of‑goods per test, delivering ≥80 % margin improvement for laboratory partners.
- Integrated compliance framework (HIPAA, HITRUST, GDPR) and audit‑ready data logging for regulated diagnostic settings.